Veterinary Therapeutic Protein and Peptide Ribosomal Display Platform

R&D Solutions

Get a quote

We're excited to learn more about your project and provide you with a customized quote tailored to your needs. Please fill out the form below, and we'll get back to you as soon as possible.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Veterinary Therapeutic Protein and Peptide Ribosomal Display Platform

Inquiry Now

Overview Ribosomal Display Services Features Service Workflow Why Choose Us

Ribosomal display is one of the cell-free technologies used for the in vitro selection and evolution of proteins and peptides from recombinant libraries. This technique ensures that individually expressed polypeptides, or phenotypes, are physically linked to their corresponding mRNA through the formation of stable Protein-Ribosome-mRNA (PRM) complexes, which act as the basis for selection. BioVenic leverages cutting-edge ribosomal display to accelerate the discovery of novel proteins and peptides. Our services cater to clients across the biotechnology and pharmaceutical industries for animal health, providing tailored solutions that encompass every stage of the discovery process. Cell-free display technology for protein and peptide development is characterized by its in vitro system, which simplifies the workflow by eliminating the need for cell cultures. It allows for precise control over reaction conditions and immediate analysis, making it an ideal tool for protein and peptide discovery.

Ribosomal Display Platform Overview

Ribosomal display platform is an innovative in vitro cell-free technology capable of protein and peptide production and evolution with exceptional diversity up to 10¹⁵. This platform leverages proprietary prokaryotic and eukaryotic display technologies. BioVenic provides a thorough ribosomal display cycle comprising five essential steps. Generally, several rounds of screening are required to separate the veterinary therapeutic proteins and peptides that bind disease targets with high affinity. The ribosomal display screens larger libraries and increases the possibility of the discovery of novel proteins and peptides since the whole process in process in vitro without the need for cell cloning.

Fig.1 The cycle of ribosomal display at BioVenic for the discovery of veterinary therapeutic proteins and peptides. (BioVenic Original) Fig.1 The ribosomal display cycle of veterinary therapeutic protein and peptide discovery. (BioVenic Original)

Ribosomal Display Services

	Description	Services
Library Construction	Create a diverse library of DNA sequences that encode the proteins or peptides of interest.	Augment the genetic diversity of the libraries to increase the likelihood of finding highly effective and unique binders. Provide quickly generated PCR constructs for early-stage research, facilitating fast iteration and testing.
Cell Generation of PRMs	The DNA library is transcribed and translated in a cell-free system to produce PRM complexes. The mRNA remains attached to the ribosome, which is still bound to the newly synthesized protein/peptide.	Offer high-fidelity protein-RNA matching, to ensure precise interactions between protein/peptide and RNA.
*Affinity Selection & In Situ* RT-PCR Recovery**	The PRM complexes are exposed to an immobilized ligand, allowing proteins with high affinity for the ligand to bind. After affinity selection, the mRNA from the bound PRM complexes is reverse-transcribed into cDNA. This cDNA serves as a template for PCR amplification.	Identify proteins or peptides with high affinity and specificity to certain targets relevant to veterinary diseases. Utilize in situ RT-PCR to recover and amplify the RNA of bound peptides or proteins, ensuring that successful binders are captured for further analysis. Conduct comparative analyses to assess the binding efficiency and specificity of various candidates for clients. Optimize the recovery process to ensure maximum yield of target-bound complexes.
Regeneration of Full-Length DNA Constructs	The recovered cDNA is used to regenerate the full-length PCR construct, which can be used in subsequent selection cycles to further refine and enrich high-affinity binders.	Provide services to regenerate full-length DNA constructs from selected RNA, facilitating multiple rounds of selection. Facilitate the regeneration of full-length constructs for repetitive screening, enhancing the throughput of discovery cycles.
Cloning, Expression, & Screening	Selected DNA sequences encoding proteins or peptides are cloned into expression vectors, expressed in suitable systems, and screened for desired properties.	Utilize advanced technologies to screen large numbers of clones for optimal binders. Conduct rigorous screening processes to evaluate the efficacy, specificity, and stability of proteins or peptides, identifying candidates most likely to succeed in veterinary therapeutic protein and peptide development.

Ribosomal Display Platform Features

Ribosomal display owns libraries with large diversity sizes (approximately 10¹⁵).
The protein remains attached to its encoding mRNA via the ribosome, linking the genetic information directly to the protein's or peptide's physical characteristics.
In vitro technique that does not rely on living cells, allowing for the direct translation of mRNA into protein-ribosome complexes.
Scalable for both small-scale research applications and large-scale industrial processes.
Minimize the bias introduced by cellular systems, offering a more accurate representation of protein characteristics.

BioVenic also provides other cell-free platforms to discover therapeutic proteins and peptides, including mRNA display, and DNA display. Please get access to other cell-free platforms via the following links:

Service Workflow

Ribosomal display technology at BioVenic starts with a comprehensive consultation to understand client goals and tailor services. We craft diverse ribosome libraries, either custom-built or selected from existing collections, targeted specifically at veterinary diseases. This approach ensures a broad capture of potential binders. Our screening process includes multiple rounds of panning that demonstrate strong affinity and specificity for the intended target. Selected promising candidates are then subjected to sequencing and in-depth characterization to evaluate their binding properties. Ultimately, we provide detailed reports and continuous support, seamlessly integrating the developed proteins or peptides into the client's research or product pipelines, fostering advances in both scientific understanding and therapeutic applications. BioVenic also offers a one-stop solution for the development of veterinary therapeutic proteins and peptides through its exhaustive phage display services, designed to meet the specific needs of each client.

Fig.2 The service workflow of veterinary therapeutic protein and peptide ribosomal display. (BioVenic Original) Fig.2 The procedural framework of ribosomal display services for veterinary therapeutic proteins and peptides. (BioVenic Original)

Why Choose Us?

In Vitro Environment

All steps are conducted in a test tube, allowing precise control over experimental conditions.

Facilitated Evolution

Enable directed evolution of proteins through mutations, with immediate screening and evaluation variants.

High-Throughput Screening

Rapid and efficient identification of candidates with strong affinity to disease targets technologies.

Rapid Iteration

Allows for faster screening of large libraries by eliminating the need for cell transformation and cultivation.

One-Stop Solution

Comprehensive services from initial consultation to production, and development..

BioVenic provides cutting-edge tools and technologies for the discovery of veterinary therapeutic proteins and peptides, enabling our clients to find effective drugs according to specific veterinary disease targets. If you have questions or need more information about our services, please don't hesitate to contact us. We are committed to delivering expert support for your research and working together to drive advancements in the field of veterinary therapeutic protein and peptide discovery.